RU-79115 (Aventis Pharma)

¹Faculty of Pharmacy, University of Toronto, ON, Canada.

Current Opinion in Investigational Drugs (London, England : 2000)

|September 27, 2001

Abstract:

Aventis Pharma AG is investigating a series of novel coumarin DNA gyrase B inhibitors, including RU-79115, as potential treatments for bacterial infections. These inhibitors have displayed potent inhibitory activity in vitro against DNA supercoiling by DNA gyrase B and have antibacterial activity. Good antibacterial activity against vancomycin- and teicoplanin-resistant enterococci was observed with most analogs (where the 3-acylamino residue was replaced with reversed isosteres). Amide derivatives were also active against novobiocin-resistant strains [335149]. RU-79115 has shown activity against Gram-positive bacteria, particularly staphylococci and enterococci, and its activity compares favorably to vancomycin. Against oxacillin- and ofloxacin-resistant staphylococci, RU-79115 had MIC50 values 7.5-fold lower than eperezolid and significantly lower than vancomycin. In vivo data suggest that the compound is safe and carries a satisfactory pharmacokinetic profile [216256], [340969], [376199]. The compound is the most potent in the series which also includes RU-78535 and RU-64135 [340969], [341039].

Related Experiment Videos

RU-79115 (Aventis Pharma)

Related Concept Videos

Peptidyl Arginine Deiminases and Neurodegenerative Diseases.

Inhibition of orotidine 5'-monophosphate decarboxylase and its therapeutic potential.

Insight into the complex and dynamic process of activation of matrix metalloproteinases.

Substrate hydrolysis by matrix metalloproteinase-9.

X-ray absorption studies of human matrix metalloproteinase-2 (MMP-2) bound to a highly selective mechanism-based inhibitor. comparison with the latent and active forms of the enzyme.

Insights into class D beta-lactamases are revealed by the crystal structure of the OXA10 enzyme from Pseudomonas aeruginosa.

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Structure-activity profiling of indazole-based derivatives as spinster homolog 2 (Spns2)-dependent S1P release inhibitors.

Triterpenoids and lignans from the stems of Tripterygium wilfordii and their hepatoprotective activities.

An integrated in vitro and in silico approach to evaluate the safety and wound healing potential of Dracocephalum moldavica L. seed oil.

Unraveling the allosteric inhibition mechanism of TLR2 by CU-CPT22: A combined DFT and enhanced sampling MD study.

Discovery of pyrimidine-based dual CDK2/TrkA inhibitors: Synthesis, antiproliferative activity, and mechanistic insights.

Oleanolic acid-selenocyanate hybrids trigger replication-associated DNA damage responses and suppress tumour growth in vitro and in vivo.

Related Experiment Videos

RU-79115 (Aventis Pharma)

Abstract:

Related Concept Videos

Related Articles